The primary purpose of this shared resource is to generate novel polyclonal and monoclonal antibody reagents, to assist investigators in characterization and optimization of these reagents, and to provide other technical assistance for antibody-related research. Availability of high quality antibody reagents is critical for understanding protein function in normal and neoplastic cells and tissues.
We aim to provide antibodies to cancer center members in a timely manner at a reduced cost, relative to commercial custom antibody services. We can also provide an expanded range of services that are not generally available from commercial sources, so that more investigators without expertise or equipment for molecular cell biology or biochemistry can successfully generate and characterize custom antibody reagents. Our most commonly used services include the generation of rabbit polyclonal antibodies, purification and/or testing of polyclonal antibody, generation of mouse polyclonal antibodies, and the generation, purification, characterization and testing of mouse monoclonal antibodies. Other services that we have provided include production and purification of bacterially expressed fusion protein antigens, antibody isotyping, cryopreservation and storage of hybridoma lines, preparation of Fab fragments from existing antibodies, adaptation of hybridoma lines to serum-free culture and recovery of poorly frozen hybridoma cell lines from other sources.

Public Health Relevance

The mission of the Antibody Shared Resource is to generate novel polyclonal and monoclonal antibody reagents, and to provide antibody-related advice and services to aid cancer center investigators in their research. It is our aim to provide these services in a timely and cost-effective manner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA054174-19S5
Application #
8637191
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-01
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
19
Fiscal Year
2013
Total Cost
$19,493
Indirect Cost
$6,454
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Katti, Sachin; Her, Bin; Srivastava, Atul K et al. (2018) High affinity interactions of Pb2+ with synaptotagmin I. Metallomics 10:1211-1222
De La Chapa, Jorge J; Singha, Prajjal Kanti; Lee, Debbie R et al. (2018) Thymol inhibits oral squamous cell carcinoma growth via mitochondria-mediated apoptosis. J Oral Pathol Med 47:674-682
Wang, Zhonghua; Bhattacharya, Akash; White, Tommy et al. (2018) Functionality of Redox-Active Cysteines Is Required for Restriction of Retroviral Replication by SAMHD1. Cell Rep 24:815-823
Hariharan, Nisha; Ashcraft, Keith A; Svatek, Robert S et al. (2018) Adipose Tissue-Secreted Factors Alter Bladder Cancer Cell Migration. J Obes 2018:9247864
Deng, Yilun; Qin, Yuejuan; Srikantan, Subramanya et al. (2018) The TMEM127 human tumor suppressor is a component of the mTORC1 lysosomal nutrient-sensing complex. Hum Mol Genet 27:1794-1808
Wei, Zhen; Panneerdoss, Subbarayalu; Timilsina, Santosh et al. (2018) Topological Characterization of Human and Mouse m5C Epitranscriptome Revealed by Bisulfite Sequencing. Int J Genomics 2018:1351964
Chiang, Huai-Chin; Zhang, Xiaowen; Zhao, Xiayan et al. (2018) Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development. Sci Rep 8:2731
Zanotto-Filho, Alfeu; Rajamanickam, Subapriya; Loranc, Eva et al. (2018) Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer Lett 425:101-115
Segovia, Jesus A; Chang, Te-Hung; Winter, Vicki T et al. (2018) NLRP3 Is a Critical Regulator of Inflammation and Innate Immune Cell Response during Mycoplasma pneumoniae Infection. Infect Immun 86:
Donegan, Jennifer J; Boley, Angela M; Lodge, Daniel J (2018) Embryonic stem cell transplants as a therapeutic strategy in a rodent model of autism. Neuropsychopharmacology 43:1789-1798

Showing the most recent 10 out of 989 publications